Autoimmune diabetes and targets for immunomodulation.

Area of Science:

• Immunology
• Endocrinology
• Autoimmune Diseases

Background:

• Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to insulin deficiency.
• Current management with exogenous insulin does not cure T1D and often results in long-term complications due to inadequate glycemic control.
• Addressing the underlying autoimmune response is critical for developing effective T1D therapies.

Purpose of the Study:

• To review actionable immunomodulatory targets for Type 1 diabetes therapies at tissue, cellular, and molecular levels.
• To discuss the role of T cells and other immune cells in T1D pathogenesis and therapeutic strategies.
• To explore emerging strategies, including microbiome modulation, for T1D prevention and treatment.

Main Methods:

• Comprehensive review of current and emerging immunomodulatory therapies for Type 1 diabetes.
• Analysis of immune cell populations, focusing on T cells, and their interactions with beta cells.
• Examination of strategies targeting specific immune cell populations, tissue relevance, and antigen specificity.
• Inclusion of microbiome-based approaches as indirect immune modulation strategies.

Main Results:

• Identified a wide range of immunomodulatory targets for T1D, including specific T cell populations.
• Highlighted advances in precise targeting based on tissue relevance and antigen specificity.
• Discussed the potential of microbiome modulation for T1D prevention.

Conclusions:

• Numerous therapeutic avenues targeting the immune system are available for Type 1 diabetes.
• Many targets require further validation in human studies.
• Precision targeting and microbiome modulation represent promising future strategies for T1D management and prevention.